Drugs / Sing2016 M2SR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03999554 | Sep 2019 → Jul 2020 | influenza | FluGen Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sing2016 M2SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03999554 ↗ |
| Modality | Vaccine | “M2-deficient single replication (M2SR) influenza vaccine” PMID 36350017 ↗ Dec 2022 |
| Route | Intranasal | “This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.” NCT03999554 ↗ |